Japanese Neurodegeneration Biotech Companies

Japanese Neurodegeneration Biotech Companies

Overview

Japanese Neurodegeneration Biotech Companies

Overview

Japan represents a significant hub for neurodegenerative disease research and drug development, with major pharmaceutical companies, innovative biotech startups, and world-class academic research institutions contributing to advances in Alzheimer's disease, Parkinson's disease, and related conditions. The country's strength in induced pluripotent stem cell (iPSC) technology, regenerative medicine, and precision medicine approaches has made it a global leader in neurodegeneration research. Japan's regulatory environment supports rapid clinical translation, and companies like Eisai have demonstrated this through the accelerated approval pathway for lecanemab in both the US and Japan["@lecanemab"].

This page catalogs Japanese companies actively developing therapies for neurodegeneration, from large multinational pharmaceutical companies like Eisai and Takeda to innovative startup biotechs and academic spin-outs emerging from institutions like Kyoto University, the University of Tokyo, and RIKEN.

Large Pharmaceutical Companies

Eisai Co., Ltd.

Eisai is a leading Japanese pharmaceutical company with a strong focus on neurology and has become globally recognized for its Alzheimer's disease research. The company co-developed lecanemab (Leqembi) with Biogen, an amyloid-beta targeting antibody approved for early Alzheimer's disease. Lecanemab represents the first disease-modifying therapy to demonstrate meaningful slowing of cognitive decline in a pivotal Phase 3 trial (Clarity AD), showing a 27% reduction in clinical decline at 18 months[@lecanemab]. Eisai has also developed lemborexant for sleep-wake disorders, addressing the circadian dysfunction commonly seen in Alzheimer's and Parkinson's disease patients.

Eisai's neuroscience pipeline includes tau aggregation inhibitors, amyloid-beta antibodies, and neuroinflammation modulators. The company maintains a robust partnership network with academic institutions including RIKEN and Kyoto University, leveraging Japan's strengths in iPSC technology for drug discovery[@eisai_annual].

• Key Programs: Lecanemab (co-developed with Biogen), tau aggregation inhibitors, amyloid-beta antibodies, anti-inflammatory approaches for neurodegeneration
• Pipeline Focus: Alzheimer's disease, Lewy body dementia, Parkinson's disease
• Notable Partnerships: Biogen (lecanemab co-development), multiple Japanese academic institutions

Takeda Pharmaceutical Company Limited

Takeda is Japan's largest pharmaceutical company and has strategically rebuilt its neuroscience pipeline after divesting its legacy CNS portfolio. The company has pursued an aggressive acquisition strategy to strengthen its neurology capabilities, acquiring companies with innovative mechanisms for neurodegenerative diseases. Takeda's neuroscience focus areas include tau immunotherapy collaborations, neuroprotective agents, and novel approaches targeting protein aggregation in both Alzheimer's and Parkinson's disease[@takeda_neur].

• Key Programs: Tau immunotherapy collaborations, neurodegenerative disease pipeline, neuroprotective agents
• Pipeline Focus: Alzheimer's disease, Parkinson's disease, rare neurological conditions
• Notable Partnerships: Collaborations with leading biotech companies for tau-targeted therapies

Daiichi Sankyo Co., Ltd.

Daiichi Sankyo has a significant CNS pipeline focusing on novel mechanisms for neurodegenerative diseases. The company is developing tau-targeted therapies and maintains active collaborations with academic institutions in Japan for neuroscience research. Daiichi Sankyo's drug discovery platform emphasizes precision medicine approaches for patient stratification.

• Key Programs: Tau protein modulators, neuroprotective agents, precision medicine for neurodegeneration
• Pipeline Focus: Alzheimer's disease
• Notable Research: Collaborations with RIKEN for tau biology research

Astellas Pharma Inc.

Astellas focuses on innovative medicine discovery in multiple therapeutic areas including urology, oncology, and immunology. The company has active research in neurodegenerative diseases with programs targeting protein aggregation and neuroinflammation. Astellas has invested significantly in gene therapy and next-generation modalities for neurological diseases.

• Key Programs: Alpha-synuclein modulators, neuroinflammation inhibitors, gene therapy approaches
• Pipeline Focus: Parkinson's disease, Alzheimer's disease
• Notable Capabilities: Gene therapy platform, cell therapy research

Mitsubishi Tanabe Pharma Corporation

A member of the Mitsubishi UFJ Financial Group, Mitsubishi Tanabe has a heritage in CNS drug development. The company has developed treatments for neurological disorders and continues to invest in research for neurodegenerative diseases, particularly in Parkinson's disease where it has market presence with existing therapies.

• Key Programs: CNS drug development, Parkinson's disease therapeutics
• Pipeline Focus: Parkinson's disease, Alzheimer's disease

Sumitomo Pharma Co., Ltd.

Sumitomo Pharma focuses on psychiatry, neurology, and oncology. The company has developed treatments for depression and schizophrenia and is expanding into neurodegenerative disease research with novel small molecule approaches.

• Key Programs: CNS therapeutics, neuroprotective agents
• Pipeline Focus: Alzheimer's disease, Parkinson's disease

Otsuka Holdings Co., Ltd.

Otsuka is known for its innovative approaches in psychiatry and neurology, having developed treatments for schizophrenia and bipolar disorder. The company is exploring novel mechanisms for neurodegenerative diseases, particularly focusing on neuroinflammation and protein aggregation pathways.

• Key Programs: CNS research, novel mechanism discovery
• Pipeline Focus: Alzheimer's disease, Parkinson's disease

Chugai Pharmaceutical Co., Ltd.

Chugai, a member of the Roche group, bridges Japanese innovation with global pharmaceutical capabilities. The company develops biologics and novel antibodies for neurodegenerative diseases, leveraging Chugai's proprietary antibody engineering technologies. Chugai has active programs in Alzheimer's disease targeting amyloid-beta and tau pathology.

• Key Programs: Antibody therapeutics for neurodegeneration, amyloid-beta antibodies, tau-targeting biologics
• Pipeline Focus: Alzheimer's disease
• Notable Capabilities: Antibody engineering, biologics manufacturing, Roche partnership

Kyowa Kirin Co., Ltd.

Kyowa Kirin focuses on specialty pharmaceuticals with strength in oncology, immunology, and nephrology. The company has expanded into neurological diseases with programs targeting neuroinflammatory pathways and pain mechanisms relevant to neurodegenerative conditions.

• Key Programs: Neuroinflammatory modulators, neurological disease pipeline
• Pipeline Focus: Neurological diseases with inflammatory components

Small Biotech and Startup Companies

Tree Pharmaceutical Co., Ltd.

Tree Pharmaceutical is an Osaka-based biotechnology company dedicated to developing novel therapeutics for neurodegenerative diseases. The company focuses on amyloid-beta and alpha-synuclein targeting approaches, leveraging Japan's strong academic research base to advance novel drug candidates through clinical development.

• Key Programs: AD/PD therapeutics targeting protein aggregation, novel small molecules
• Pipeline Status: Active drug discovery programs in preclinical and early clinical stages

Accerise Inc.

Accerise is a Tokyo-based drug discovery company utilizing structure-based design and computational approaches to develop therapeutics for neurodegenerative diseases. The company's proprietary platform enables rapid optimization of drug candidates targeting previously undruggable proteins involved in neurodegeneration.

• Key Programs: Novel enzyme inhibitors, computational drug design, protein structure-based optimization
• Notable Capabilities: Cryo-EM and X-ray crystallography for structural biology

Kinevo Inc.

Kinevo is a Tokyo-based biotechnology company focused on developing therapeutics targeting mitochondrial dysfunction in neurodegenerative diseases. Mitochondrial dysfunction is increasingly recognized as a central mechanism in both Alzheimer's and Parkinson's disease pathogenesis, making this a high-value target area.

• Key Programs: Mitochondrial protectors, neuroprotective agents targeting electron transport chain dysfunction
• Research Focus: Developing compounds that preserve mitochondrial function under conditions of oxidative stress

CureApp, Inc.

CureApp is a Tokyo-based company developing digital therapeutics (DTx) for Alzheimer's disease and Parkinson's disease. The company takes a software-as-medical-device approach, developing smartphone-based interventions that can modify disease progression through cognitive training, behavioral modification, and remote monitoring.

• Key Programs: Digital therapeutics for cognitive impairment, apps for Parkinson's disease management
• Notable Achievement: First digital therapeutic approved for Alzheimer's disease in Japan

Peptidream Inc.

Peptidream is a Tokyo-based company with a proprietary peptide discovery platform that generates constrained cyclic peptides with drug-like properties. The company's technology enables development of peptides that can target protein-protein interactions that are difficult to address with small molecules, making it valuable for neurodegenerative disease targets.

• Key Programs: Peptide therapeutics for neurodegeneration, drug discovery platform services
• Notable Partnerships: Multiple global pharmaceutical collaborations for peptide drug development

Helios Inc.

Helios is a Japanese biotech company developing innovative therapies for neurodegenerative diseases through small molecule drugs and regenerative medicine approaches. The company has a pipeline targeting Alzheimer's disease, Parkinson's disease, and ALS, including tau aggregation inhibitors and alpha-synuclein modulators.

• Key Programs: HEL-101 (tau aggregation inhibitor), HEL-201 (alpha-synuclein modulator)
• Pipeline Stage: Preclinical and early clinical development

RNP Inc.

RNP Inc. specializes in RNA-based therapeutics and diagnostics for neurodegenerative diseases. The company is developing antisense oligonucleotides (ASO) and RNAi therapeutics targeting genetic risk factors and disease-driving proteins in Alzheimer's and Parkinson's disease.

• Key Programs: RNP-401 (APOE4 ASO for Alzheimer's disease), RNP-501 (alpha-synuclein RNAi for Parkinson's disease)
• Research Focus: Genetic causes and risk factors for neurodegeneration

Kinexx Co., Ltd.

Kinexx is a Japanese biotech company focused on developing therapies for protein aggregation diseases, particularly neurodegenerative disorders. The company targets abnormal protein folding and aggregation that characterizes diseases like Alzheimer's and Parkinson's.

• Mechanism: Protein aggregation inhibitors targeting misfolded proteins
• Pipeline Focus: Alzheimer's disease, Parkinson's disease

Nobelpharma Co., Ltd.

Nobelpharma focuses on orphan diseases and has developed drugs for rare conditions. The company has interest in neurological orphan diseases and collaborates with academic institutions on neurodegenerative research.

• Focus: Rare neurological diseases, CNS disorders, orphan disease therapeutics

ID Pharma Co., Ltd.

ID Pharma is a Japanese biotech specializing in gene therapy and viral vector technology. The company provides contract manufacturing services and develops gene therapies for various diseases, including neurological conditions.

• Technology: Gene therapy, viral vectors (AAV, lentivirus), contract manufacturing
• Focus: Neurological gene therapy, AAV vector development

MedRx Co., Ltd.

MedRx develops medical devices and diagnostic tools for neurological diseases, in addition to therapeutic programs. The company focuses on early diagnosis and monitoring of neurodegenerative conditions.

• Focus: Diagnostics, neurological assessment tools, companion diagnostics for neurodegenerative diseases

ReproCELL Inc.

ReproCELL is a Japanese biotechnology company specializing in induced pluripotent stem cell (iPSC) technology and regenerative medicine. Founded in 2013 as a spin-out from Kyoto University's CiRA, ReproCELL provides iPSC-derived products and services for drug discovery, with disease models for Alzheimer's disease and Parkinson's disease.

• Key Programs: iPSC-derived neural cells, disease modeling for AD/PD, drug screening services
• Notable Capability: iPSC technology from Kyoto University licensing

Academic Spin-outs and Research Ventures

Renascience Inc.

Renascience is a Tokyo-based company developing iPSC-based cell therapies and gene therapies for neurodegenerative diseases. The company is developing disease-modifying therapies that address the underlying pathology of Alzheimer's and Parkinson's disease rather than just managing symptoms.

• Key Programs: iPSC cell therapy for neurodegeneration, gene therapy approaches
• Research Focus: Cell replacement and gene correction strategies

SanBio Co., Ltd.

SanBio is a Tokyo-based regenerative medicine company developing cell therapy products for neurological disorders. The company's lead product candidate SB623 is a cell therapy product being evaluated for stroke recovery and traumatic brain injury.

• Key Programs: SB623 cell therapy for stroke and TBI, regenerative medicine for CNS disorders
• Pipeline Stage: Clinical development for neurological recovery

Healios K.K.

Healios is a Tokyo-based iPSC company developing cell therapies for various diseases including ischemic stroke. The company leverages Japan's leadership in iPSC technology to develop allogeneic cell therapies.

• Key Programs: iPSC-derived cell therapies for stroke and vascular diseases
• Partnerships: Multiple collaborations with academic institutions

Sosei Group Corporation

Sosei Group is a Tokyo-based GPCR-focused drug discovery company, acquired by Novo Nordisk in 2023. The company developed a proprietary structure-based drug design platform (StaR technology) that enables optimization of GPCR-targeted therapeutics.

• Key Programs: GPCR modulators for neurodegeneration, drug discovery platform
• Notable: Novo Nordisk acquisition validating the company's platform value

Kyorin Pharmaceutical Co., Ltd.

Kyorin Pharmaceutical is a Tokyo-based company with focus on CNS diseases and immunology. The company has a pipeline of neurology therapeutics under development and maintains partnerships with academic researchers in Japan.

• Key Programs: Neurology pipeline, CNS therapeutics
• Research Focus: Drug discovery for neurological diseases

Kissei Pharmaceutical Co., Ltd.

Kissei Pharmaceutical is a Matsumoto-based company developing treatments for neurological disorders. The company has research programs focused on novel mechanisms for neurodegenerative diseases.

• Key Programs: Neurology therapeutics, neuroprotective agents
• Focus: Parkinson's disease, other neurodegenerative conditions

Nippon Shinyaku Co., Ltd.

Nippon Shinyaku is a Kyoto-based company focused on rare diseases and oligonucleotide therapeutics. The company's expertise in oligonucleotide chemistry positions it for nucleic acid-based therapies for neurodegenerative diseases.

• Key Programs: Oligonucleotide therapeutics, rare disease treatments
• Capabilities: Nucleic acid chemistry, delivery technologies

RIBOMIC Inc.

RIBOMIC is a Tokyo-based RNA therapeutics company specializing in RNA aptamer technology for ocular and CNS disorders. RNA aptamers offer an alternative to antibody therapeutics with potentially better tissue penetration and manufacturing advantages.

• Key Programs: RNA aptamers for neurodegeneration, ocular disease therapeutics
• Technology: SELEX-based aptamer discovery

NanoCarrier Co., Ltd.

NanoCarrier is a Tokyo-based drug delivery company using polymeric micelle technology for targeted therapeutics. The company's delivery platform can improve brain penetration of neuroprotective compounds.

• Key Programs: Brain-targeted drug delivery, polymeric micelle formulations
• Applications: CNS drug delivery for neurodegenerative diseases

Daiwa Sangyo Co., Ltd.

Daiwa Sangyo is a Japanese manufacturer of pharmaceutical intermediates for CNS drugs and provides contract manufacturing services. The company supports both Japanese and international pharmaceutical companies with manufacturing capabilities.

• Key Programs: CNS pharmaceutical intermediates, contract manufacturing services
• Focus: Supply chain support for neurodegeneration therapeutics

Kaken Pharmaceutical Co., Ltd.

Kaken Pharmaceutical is a Tokyo-based pharmaceutical company with focus on CNS disorders and neuropathic pain treatments. The company has research programs addressing pain and neurological symptoms associated with neurodegenerative diseases.

• Key Programs: CNS therapeutics, neuropathic pain treatments
• Pipeline Focus: Symptomatic management of neurodegenerative conditions

University Spin-out Companies

[Krasue Inc.](/institutions/krasue-inc) (from Kyoto University)

• Focus: Mitochondrial dysfunction in neurodegeneration
• Approach: Novel mitochondria-targeting compounds (PGC-1alpha activators)
• Key Programs: KRS-001 (Parkinson's disease), KRS-002 (Alzheimer's disease)

• Focus: Neuroimaging biomarkers for Alzheimer's disease diagnosis
• Approach: Novel PET tracers and imaging biomarkers
• Key Programs: NG-201 (neuroinflammation PET), NG-202 (synaptic density), NG-203 (alpha-synuclein PET)

• Focus: Synaptic protection and repair
• Approach: Synaptic function modulators
• Key Programs: SH-201 (PSD-95 stabilizer), SH-202 (NMDA receptor modulator)

• Focus: Protein degradation technologies
• Approach: Targeted protein degradation for neurodegenerative proteins
• Key Programs: TB-301 (tau PROTAC), TB-302 (alpha-synuclein degrader)

• Focus: Novel drug delivery systems
• Approach: Brain-targeted nanopharmaceuticals (nanoparticle BBB transcytosis)
• Key Programs: TN-401 (mitochondrial drug delivery), TN-402 (antibody brain delivery)

• Focus: Neurotrophic factors
• Approach: BDNF mimetics for Alzheimer's disease
• Key Programs: ONT-301 (TrkB agonist), ONT-302 (BDNF mimetic peptide)

• Focus: Gut-brain axis in neurodegeneration
• Research: Microbiome-based therapies for Parkinson's disease
• Key Programs: RS-301 (defined bacterial consortium), RS-302 (butyrate derivative)

Research Organizations

RIKEN Center for Brain Science

RIKEN is Japan's flagship research institute with a world-renowned brain science center. Researchers at RIKEN have made significant contributions to understanding amyloid-beta toxicity, tau pathology, and alpha-synuclein in neurodegenerative diseases[@riken_brain]. The center houses state-of-the-art imaging facilities, iPSC research capabilities, and maintains active collaborations with pharmaceutical companies for translational research.

• Research Areas: Basic neuroscience, amyloid biology, tau pathology, iPSC models, neuroimaging
• Notable Programs: Brain/MINDS project for neuroimaging, iPSC bank for neurodegenerative disease research

National Center of Neurology and Psychiatry (NCNP)

NCNP is Japan's only national research hospital specializing in neurology and psychiatry. The institute conducts clinical research on Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions, and maintains patient registries and biobanks that support drug discovery efforts.

• Research Areas: Clinical research, disease registries, therapeutic trials, epidemiological studies

Tokyo Metropolitan Institute for Neuroscience

This institute conducts fundamental and translational research on neurodegenerative diseases, with particular strength in Parkinson's disease research and movement disorders.

• Research Areas: Movement disorders, basal ganglia physiology, Parkinson's disease mechanisms

Key Therapeutic Approaches in Japan

Amyloid-Targeting Therapies

Japanese companies, particularly Eisai, have led global efforts in amyloid-beta antibody development. Lecanemab represents a major breakthrough in disease modification for early Alzheimer's disease, demonstrating that removing amyloid-beta from the brain can slow cognitive decline[@lecanemab]. Japanese researchers at RIKEN have contributed fundamental discoveries about amyloid-beta structure and toxicity mechanisms that informed these therapeutic approaches.

Tau Research

Multiple Japanese institutions and companies are pursuing tau-targeted therapies:

• Tau aggregation inhibitors
• Tau immunotherapy
• Tau phosphorylation modulators
• Tau spreading blockers

Protein Aggregation Inhibitors

Japanese biotech companies are developing small molecules targeting abnormal protein aggregation in AD and PD, addressing both amyloid-beta and alpha-synuclein pathologies. The country's strength in structural biology and cryo-EM has accelerated target identification and drug design.

Neuroinflammation Modulation

Research into neuroinflammation as a therapeutic target is active in Japan, with companies developing anti-inflammatory approaches for neurodegenerative diseases. This includes microglia modulation, NLRP3 inflammasome inhibitors, and cytokine-targeting strategies.

Gene Therapy

Japanese companies like ID Pharma are advancing gene therapy approaches for neurological diseases, including potential applications in neurodegenerative conditions. AAV vector development and gene editing technologies are active research areas.

Regenerative Medicine

Japan's leadership in iPSC technology supports cell replacement therapies for Parkinson's disease and other neurodegenerative conditions. Companies like Renascience, SanBio, and Healios are developing cell-based approaches that could restore lost neuronal populations.

Clinical Trial Landscape

Japan offers a favorable environment for clinical trials in neurodegenerative diseases, with:

• Strong academic medical centers with experienced investigators
• Well-characterized patient populations with detailed longitudinal data
• Government support for clinical research through AMED[@amed]
• Efficient regulatory pathways with parallel consultation options
• Growing receptivity to international multi-center trials

Funding and Support

AMED (Japan Agency for Medical Research and Development)

• Strategic Research Programs for Brain Sciences
• Practical Research Project for Nervous System Diseases
• International Collaborative Research Programs
• Research grants for drug discovery and clinical development

Regional Innovation Hubs

Japan has established regional innovation hubs supporting biotech development:

• Tokyo Bio Innovation Hub - biotech startup ecosystem
• Kansai Science City - research and commercialization center
• Kobe Biomedical Innovation Cluster - medical technology development

University Technology Transfer

Japanese universities have become increasingly active in spin-out company formation, with technology transfer offices (TLOs) supporting commercialization of academic research in neurodegeneration.

Cross-Linking

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Biotechnology Companies](/companies/biotechnology-companies)

See Also

• [Canadian Neurodegeneration Biotech Companies](/companies/canadian-neurodegeneration-biotech)
• [Korean Biotech Companies in Neurodegeneration](/companies/korean-neurodegeneration-biotech)
• [Singapore/Asia-Pacific Neurodegeneration Biotech Companies](/companies/singapore-asia-pacific-neurodegeneration-biotech)
• [Australian Neurodegeneration Biotech Companies](/companies/australian-neurodegeneration-biotech)